Pharmacologic treatments for covid-19 patients

Hydroxychloroquine+Ribavirin vs Standard care

This comparison will not be updated. Last search date 28 Feb, 2022.


Hospitalized patients

Forest plots
(last update: 2022-04-12)

Summary of findings
(last update: 2022-04-27)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=426

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
CTRI/2020/06/025575
Panda PK, Clin Pharmacol, 2021
Full text
Full text
Commentary
Commentary
No specific funding

HCQ+RBV

LPV/r+RBV

HCQ+RBV

Standard care

Standard care

LPV/r+RBV

RCT Patients with confirmed COVID-19 (severe-critical) admitted to a single center in India. N=71
Some concerns
Details

Full description

CTRI/2020/06/025575
Panda PK(2), Clin Pharmacol, 2021
Full text
Full text
Commentary
Commentary
No specific funding

HCQ+RBV

Standard care

RCT Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in India. N=40
Some concerns
Details

Full description